Diabetes, Nutrition and endocrinological diseases
PRINCIPAL INVESTIGATORS
- Montserrat Nacher Garcia
- Elisabet Estil·Les Altimiras
- Lydia Escolano Soriano
- Nuria Vilarrasa García
- Nuria Virgili Casas
- Manuel Pérez Maraver
- Patricia San José Terrón
CLINICAL RESEARCHERS
- Jorge Caballero Corchuelo
- Laura Hernández Montoliu
- Fernando Guerrero Pérez
- Rafael López Urdiales
POSTDOCTORAL RESEARCHERS
- Claudia Fernandez Alegre
PREDOCTORAL RESEARCHERS
- Daniel Soriano Medrano
- Kevin Andrés Rivera Loor
SCIENTIFIC SUPPORT
- Maria Ferrés Prat
- Marta Campos Gil
- Esther Obea Gómez
MANAGEMENT SUPPORT
- Maria Isabel Ramis Juan
Translational Medicine
Diabetes and Metabolism
Scientific production
26
PAPERS
Average IF: 5,467
11
LED PAPER
Average IF: 5,21
5 PUBLICATIONS IN FIRST DECILE
12 PUBLICATIONS IN FIRST QUARTILE
16 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Villanueva Carmona,T;Cedo,L;Madeira,A;Ceperuelo Mallafre,V;Rodriguez Pena,MM;Nunez Roa,C;Maymo Masip,E et al, SUCNR1 signaling in adipocytes controls energy metabolism by modulating circadian clock and leptin expression, Cell Metab., 2023;35(4):doi:10.1016/j.cmet.2023.03.004
- Guerrero Pérez,F;Vilarrasa,N;Huánuco,LV;Busquets,J;Secanella,L;Vercher Conejero,JL;Vidal,N et al, Ectopic insulinoma: a systematic review, Rev. Endocr. Metab. Disord., 2023;24(6):1135-1146, doi:10.1007/s11154-023-09824-2
- Montero,E;Bujaldón,R;Montanya,E;Calle Pascual,AL;Rojo Martínez,G;Castaño,L;Franch Nadal,J et al, Cross-sectional association between severe periodontitis and diabetes mellitus: A nation-wide cohort study, J. Clin. Periodontol., 2023;51(4):368-379, doi:10.1111/jcpe.13937
- Rosenstock,J;Cariou,B;Eliasson,J;Frappin,G;Kaltoft,MS;Montanya,E;Knop,FK, Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies, Diabetes Obes. Metab., 2023;26(2):532-539, doi:10.1111/dom.15339
- Meier,JJ;Bardtrum,L;Cheng,A;Malling,B;Montanya,E;Wagner,L;Pratley,RE, Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis, Diabetes Obes. Metab., 2023;25(4):1130-1135, doi:10.1111/dom.14957
Research highlights
PROJECTS
4 Ongoing competitive projects
6 Ongoing clinical trials
PUBLISHED WORKS
2 Clinical Guidelines
1 Thesis
NETWORKS
CIBERDEM
AGAUR SGR GRC
Selected projects
- 20FIS020. Role of ß-cell dedifferentiation in human islets failure and contribution of endoplasmic reticulum stress and mitochondrial dysfunction. Instituto de Salud Carlos III (ISCIII). Budget: 288.282,5€. 2020-2024. PI: Montanya Mias, Eduard.
- FIS22048. Factores pronósticos y predictores de remisión de diabetes en técnicas de cirugía bariátrica hipoabsortivas: Estudio aleatorizado comparando Cruce Duodenal, SADI-S y Minigastric Bypass. Instituto de Salud Carlos III (ISCIII). Budget: 251.680€. 2023-2025. PI: Vilarrasa García, Nuria.
- FIS22029. Plasticidad de la masa celular beta en la obesidad y la diabetes tipo 2: papel de las células ductales pancreáticas. Instituto de Salud Carlos III (ISCIII). Budget: 147.620€. 2023-2025. PI: Montanya Mias, Eduard.
- INT21020. Comprehensive characterization of human ductal epithelium to identify endogenous progenitors as beta cell source. EUROPEAN FOUNDATION FOR THE STUDY OF DIABETES (EFSD). Budget: 50.448€. 2022-2024. PI: Montanya Mias, Eduard; Rovira Clusellas, Meritxell.
- 19ACL090. Efectos de semaglutida a largo plazo en la retinopatía diabetica en sujectos con diabetes tipo 2 (FOCUS). Novartis Farmacéutica, S.A.;Novo Nordisk A/S;Novo Nordisk Pharma. Budget: 96.296€. 2019- . PI: Montanya Mias, Eduard.